Abstract: The present invention relates to a method for increased production of a secreted, recombinant protein product through the introduction of molecular chaperones in a mammalian host cell. The present invention also relates to a mammalian host cell with enhanced expression of a secreted recombinant protein product by coexpressing at least one chaperone protein.
Abstract: The present invention provides a human photoaged skin model and an animal model, and a method of making the same, for evaluating cosmetics and similar products in terms of their anti-aging or rejuvenating effect.
Abstract: The present invention features colony-forming unit cells derived from the chorion of human placenta and describes compositions and methods for the uses of chorionic cells and their products for therapeutic purposes based upon production and release of multiple growth factors and cytokines by these cells stimulating tissue regeneration independent of engraftment, as well as differentiation into a specific cell type.
Abstract: Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of cells comprising disaggregated adipose-derived stem cells, mixing the concentrated population of adipose-derived cells comprising disaggregated adipose-derived cells with a portion of unprocessed, intact, non-disaggregated adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed.
Abstract: The invention features a method of identifying oocytes with a risk of reproductive failure and/or aneuploidy based on a telomere length assay.
Abstract: Disclosed herein are methods for the treatment of traumatic brain injury by transplantation of cells descended from marrow adherent stem cells that express an exogenous Notch intracellular domain. The transplanted cells form a pathway along which endogenous neurogenic cells proliferate and migrate from the subventricular zone to the site of injury.
Type:
Application
Filed:
March 13, 2013
Publication date:
July 3, 2014
Applicants:
UNIVERSITY OF SOUTH FLORIDA, SANBIO, INC.
Inventors:
SanBio, Inc, University of South Florida
Abstract: Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.
Type:
Application
Filed:
December 19, 2013
Publication date:
July 3, 2014
Applicant:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Inventors:
Carl H. June, James L. Riley, Marcela Maus, Anna Thomas, Robert Vonderheide
Abstract: The present invention relates to the use of certain polymers as a substrate for stem cell, such as pluripotent stem cell growth and/or culture. The present invention also relates to articles such as tissue culture materials and cell culture devices comprising at least one polymer hydrogel as described herein.
Type:
Application
Filed:
June 14, 2012
Publication date:
July 3, 2014
Inventors:
Mark Bradley, Paul Alexandre De Sousa, Rong Zhang, Heidi Katharina Mjoseng
Abstract: The present invention provides a method of artificially repressing gene expression, which is simpler to design than conventional methods (the RNAi, ribozyme and antisense methods) and which allows for easier confirmation of the effect. A method of inhibiting the translation reaction of a target gene, comprising cutting out a part of the poly(A) tail and/or 3?-terminal sequence of the target mRNA is provided.
Type:
Application
Filed:
July 17, 2012
Publication date:
July 3, 2014
Applicants:
YOSHINDO INC., PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, TOKYO INSTITUTE OF TECHNOLOGY
Abstract: Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.
Type:
Application
Filed:
March 22, 2013
Publication date:
July 3, 2014
Applicant:
CRUCELL HOLLAND B.V.
Inventors:
KATARINA RADOSEVIC, JEROME H. H. V. CUSTERS, JORT VELLINGA, MYRA N. WIDJOJOATMODJO
Abstract: A carrier for expansion of pluripotent stem cells is provided, wherein the carrier comprises a substrate comprising one or more outer surfaces, wherein the one or more outer surfaces are modified with gas plasma treatment, and one or more structured indentations on one or more of the outer surfaces. The carrier has a length at least about 0.2 mm, a width at least about 0.2 mm, and a height in a range from about 0.05 mm to 1.2 mm and each of the structured indentations has a major axis in a range from about 0.1 mm to 0.5 mm, a minor axis in a range from about 0.1 mm to 0.5 mm and a depth in a range from about 0.025 mm to about 0.5 mm. A method of making the carrier, and culturing stromal cells using the same carrier are also provided.
Abstract: The present invention relates to a method for increased production of a secreted, recombinant protein product through the introduction of molecular chaperones in a mammalian host cell. The present invention also relates to a mammalian host cell with enhanced expression of a secreted recombinant protein product by coexpressing at least one chaperone protein.
Abstract: The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production is mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.
Type:
Grant
Filed:
April 15, 2013
Date of Patent:
July 1, 2014
Assignee:
Nordmark Arzneimittel GmbH & Co. KG
Inventors:
Manfred Kurfuerst, Christian Raemsch, Nicole Raemsch-Guenther, Olaf Friedrich, Silke Huettler, Daniel Brandhorst, Thierry Berney, Pascal Bucher, Heide Brandhorst
Abstract: Aspects of the present invention include methods and compositions related to the production and use of embryonic progenitor cell types useful in the generation of cartilage, bone, choroid plexus, tendon, lipasin-secreting adipocytes, and other differentiated cell types useful in research and therapy.
Type:
Application
Filed:
October 8, 2013
Publication date:
June 26, 2014
Inventors:
Michael West, Karen Chapman, Hal Sternberg, Francois Binette
Abstract: Described herein are methods to bind a compound to the SH2 domain of Src in a Src-expressing cell which includes contacting a compound comprising an amino acid compound to a Src-expressing cell; and binding a compound to the SH2 domain of Src.
Abstract: The present invention discloses a stem cell culture medium and its applications as well as a stem cell culture method. The said stem cell culture medium contains no serum. The said stem cell culture medium contains amino acids, vitamins, salts, lipids, cytokines and protein polypeptides. The said stem cell culture medium is suitable for rapid culture of stem cells derived from human and mammalian tissues, including but not limited to, adipose mesenchymal stem cells, bone marrow mesenchymal stem cells and umbilical cord blood stem cells. The said culture medium can increase the proliferation speed of the stem cells 3-5 times, without any affects on their differentiation potentials. Comparing the said stem cell culture medium to a routine culture medium, the said culture medium is not only able to proliferate stem cells derived from different sources more rapidly and achieve more proliferation generations, but also keep their differentiation potentials well.
Type:
Application
Filed:
January 31, 2013
Publication date:
June 26, 2014
Inventors:
Xiaoqing Liu, Ming Ying, Guangfeng Chen, Longpo Zheng
Abstract: A method for manufacturing at least one kind of eukaryotic cells or a biosynthetic substance derived from the eukaryotic cells by proliferating the cells, which includes preparing an artificially synthesized peptide for promoting proliferation of the at least one kind of eukaryotic cells, incubating the eukaryotic cells in a culture medium, and adding the synthesized peptide at least once to the culture medium during the incubation process. The synthesized peptide includes an amino acid sequence selected from SEQ ID NOS: 1 to 18, and an amino acid sequence selected from SEQ ID NOS: 19 to 97.
Type:
Application
Filed:
January 24, 2014
Publication date:
June 26, 2014
Applicants:
JAPAN TISSUE ENGINEERING CO., LTD., TOAGOSEI CO. LTD.
Abstract: Described are novel variants of APRIL that modulate signaling via receptor-specific agonist activity, and nucleic acids encoding these variant proteins. Further described is the use of these novel proteins in the treatment of APRIL-associated disorders, in particular, pathologies of the immune system and oncological disorders.
Type:
Application
Filed:
December 13, 2013
Publication date:
June 26, 2014
Applicants:
Institucio Catalana de Recerca I Estudis Avancats (ICREA), Fundacio Privada Centre de Regulacio Genomica (CRG)
Inventors:
Luis Serrano Pubul, Albert Martinus Van Der Sloot, Jan Paul Medema, Fiona Clare Kimberley
Abstract: We have disclosed an induced pluripotent stem cell and the method of preparing the induced pluripotent stem cell from a human umbilical cord tissue-derived cell. More particularly, we have disclosed a human umbilical cord tissue-derived iPS cell which may be differentiated into cells of ectoderm, mesoderm, and endoderm lineages.
Type:
Application
Filed:
November 21, 2013
Publication date:
June 26, 2014
Inventors:
Charito Buensuceso, Agineszka Seyda, David C. Colter, Sridevi Dhanaraj, Brian C. Kramer
Abstract: Methods are provided for treating a vaccine containing infectious particles which may be viral, bacterial, and/or cellular in nature. Preferred methods include the steps of adding an effective, non-toxic amount of an endogenous photosensitizer to the fluid and exposing the fluid to photoradiation sufficient to inactivate the infectious particles but not enough to damage the antigenic characteristics of the infectious particles.
Abstract: The invention relates to diagnostic and therapeutic tools and applications, particularly useful in diseases that affect vascular health and in inflammatory diseases. In particular, said diagnostic and therapeutic tools employ suitable detection or modulation of endothelial glycocalyx.
Abstract: A method to determine an analyte concentration of an anticoagulated plasma by performing at least two different measurements on a mixture of a blood sample corresponding to said anticoagulant plasma and of liquid reagent is described. The method comprises a) mixing a volume of said blood sample with a five-fold, or more, volume of said liquid reagent, b) performing said at least two measurements on said mixture, at least one of which correlates with the hematocrit of said blood sample and at least one of which correlates with said analyte concentration, and c) computing the results from the measurements when the volumes in a) are precise and accurate or when the hematocrit of said blood sample in b) is known to determine said analyte concentration of said anticoagulated plasma. In addition, a measurement and determination device for performing measurements on blood, anticoagulated blood and/or anticoagulated plasma samples, and an equipment kit are described.
Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
Type:
Application
Filed:
January 23, 2014
Publication date:
June 19, 2014
Applicants:
ALTIF LABORATORIES, TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
Abstract: Provided is a method of dedifferentiating somatic cells using embryonic stem cell-derived microvesicles. Particularly, a method of preparing induced pluripotent stem cells by treating a composition including embryonic stem cell-derived microvesicles to the somatic cells. According to the method of preparing induced pluripotent stem cells, the dedifferentiation of the somatic cells may be efficiently performed without side effects using the embryonic stem cell-derived microvesicles, and moreover, the method is expected to be very useful in developing a cell therapy product having immunocompatibilities by individuals.
Type:
Application
Filed:
April 19, 2012
Publication date:
June 19, 2014
Applicant:
POSTECH ACADEMY-INDUSTRY FOUNDATION
Inventors:
Jae-Sung Park, Yong Song Gho, Yoon Keun Kim, Jun Ho Kim, Su Chul Jang, Namwoo Yi, Dayeong Jeong, Eun-Jeong Choi
Abstract: Provided in the present invention are adult stem cells derived from human skin dermis, and a method for isolating same. Further provided in the present invention are osteoblastic cells and adipocytes differentiated from the adult stem cells derived from human skin dermis, and a differentiation method therefor. Further provided in the present invention is a composition for osteogenesis or lipogenesis containing the stem cells, osteoblastic cells, or adipocytes. The isolation method of the present invention enables the adult stem cells derived from human skin dermis to be obtained in an easy and simple manner at a high yield rate. Genes and growth factors which are specifically expressed in the adult stem cells derived from human skin dermis isolated using the method can be separated, identified, and used later.
Type:
Application
Filed:
August 24, 2012
Publication date:
June 19, 2014
Applicant:
AMOREPACIFIC CORPORATION
Inventors:
Joong Hyun Shim, Seung Ha Yang, Tae Ryong Lee, Hak Hee Kang, Dong Wook Shin
Abstract: This invention provides for methods of growing anchorage-dependent cells (e.g. hUTC) in culture medium comprising amino acids, vitamins, salts nucleosides, insulin, transferrin, ethanolamine and sodium selenium, wherein the culture medium is supplemented with serum. The method further comprises addition of a serum-free nutrient solution comprising amino acids, vitamins, salts nucleosides, insulin, transferrin, ethanolamine and sodium selenium. The invention also provides for culture media and serum-free nutrient solutions for growing anchorage-dependent cells.
Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
Type:
Grant
Filed:
May 13, 2011
Date of Patent:
June 17, 2014
Assignee:
Anthrogenesis Corporation
Inventors:
James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
Abstract: Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
Type:
Grant
Filed:
February 13, 2013
Date of Patent:
June 17, 2014
Assignee:
aTyr Pharma, Inc.
Inventors:
Jie Zhou, Ching-Fun Lau, Zhiwen Xu, Wing-Sze Lo, Kristi Helen Piehl, Leslie Ann Greene
Abstract: An improved method of producing differentiated progenitor cells comprising obtaining inner cell mass cells from a blastocyst and inducing differentiation of the inner cell mass cells to produce differentiated progenitor cells. The differentiated progenitor cells may be transfected such that there is an addition, deletion or alteration of a desired gene. The differentiated progenitor cells are useful in cell therapy and as a I source of cells for the production of tissues and organs for transplantation. Also provided is a method of producing a lineage-defective human embryonic stem cell.
Type:
Grant
Filed:
May 16, 2008
Date of Patent:
June 17, 2014
Assignee:
Advanced Cell Technology
Inventors:
Jose Cibelli, Michael D. West, Robert Lanza
Abstract: The present invention relates to the use of a female germinal cell (egg) extract of pluricellular organisms in M-phase of the cell cycle for a mitotic remodeling of chromosomes of donor cells of pluricellular organisms, wherein the mitotic remodeling confers to the nucleus of the donor cells the ability to adapt themselves to the early embryonic development, in particular to the replication phases, in order to carry out the embryonic development or to obtain stem cells.
Type:
Grant
Filed:
September 29, 2006
Date of Patent:
June 17, 2014
Assignee:
Centre National de la Recherche Scientifique
Abstract: The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.
Type:
Application
Filed:
November 14, 2013
Publication date:
June 12, 2014
Inventors:
CAROLA LEUSCHNER, HECTOR ALILA, WILLIAM HANSEL
Abstract: Described is an isolated somatic stem cell that is 2 to less than 6 micrometer in size and Lgr5+. Methods of preparing and using the cell are also described.
Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.
Type:
Application
Filed:
November 27, 2013
Publication date:
June 12, 2014
Applicant:
BioMarin Pharmaceutical Inc.
Inventors:
Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
Abstract: Provided are compositions, kits, and methods for separating cells including complexes of at least one type of linker capable of binding to an antibody or antigen binding fragment and a solid phase.
Type:
Application
Filed:
April 23, 2013
Publication date:
June 12, 2014
Applicant:
Samsung Electronics Co., Ltd.
Inventors:
Kyung-yeon HAN, Yeon-jeong KIM, Jong-myeon PARK, Chang-eun YOO
Abstract: Described are mutant Nav1.7 sodium channel alpha-subunits and nucleic acid sequences encoding such mutants. Further described are methods for characterizing a nucleic acid sequence that encodes a Nav1.7 sodium channel alpha-subunit, methods for determining a Nav1.7 haplotype, methods for determining a subject's predisposition to a neurologic disorder associated with a sodium channel mutation, and methods of identifying a compound that modulates mutant Nav1.7 sodium channels. Other materials, compositions, articles, devices, and methods relating to mutant Nav1.7 sodium channels are also described herein.
Abstract: Disclosed are an amphipathic peptide-lipase conjugate with enhanced lipase activity, a polynucleotide coding for the conjugate, an expression vector carrying the polynucleotide, a transformant anchoring the expression vector therein, a method for preparing the conjugate, a lipolysis method using the conjugate, and a method for producing biodiesel using the lipase.
Type:
Application
Filed:
August 10, 2012
Publication date:
June 12, 2014
Inventors:
Sun-Chang Kim, Bong Hyun Sung, Kyung Seok Yang, Jun Hyoung Lee, Ki Jung Lim, Myung Keun Park
Abstract: Based at least in part on an understanding of the mechanisms by which small RNAs (e.g., naturally-occurring miRNAs) mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number of mismatches tolerated, the effect of the position of the mismatches, etc. Such rules are useful, in particular, in the design of improved RNAi-mediating agents which allow for more exact control of the efficacy of RNA silencing.
Abstract: The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.
Type:
Application
Filed:
March 14, 2013
Publication date:
June 12, 2014
Inventors:
Katherine E. Varley, Richard M. Myers, Brian S. Roberts, Jason Gertz, Donald J. Buchsbaum, Andres Forero-Torres, Albert F. LoBuglio
Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of pancreatic endoderm cells, wherein the initial seeding density of undifferentiated epluripotent cells is defined.
Abstract: The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence genes expressed in cancer (e.g., Eg5, EGFR or XIAP) and methods of using such nucleic acid-lipid particles to silence Eg5, EGFR or XIAP gene expression.
Type:
Application
Filed:
October 30, 2013
Publication date:
June 12, 2014
Applicant:
Alnylam Pharmaceuticals, Inc.
Inventors:
Ian MacLachlan, Adam Judge, Vandana Sood, James Heyes, Lloyd B. Jeffs, Lorne Palmer
Abstract: A main object of the present invention is to provide a technique to produce iPS cells with less burden on the patient and with high establishment efficiency. iPS cells can be efficiently produced with significantly improved establishment efficiency by selecting cells derived from oral mucosa and introducing, into the cells, reprogramming factors capable of inducing the cells into pluripotent stem cells.
Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.
Type:
Grant
Filed:
November 2, 2009
Date of Patent:
June 10, 2014
Assignee:
Green Cross Corporation
Inventors:
Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Yong Nam Shin, Kyung Hwan Ryoo, Dong Hyuck Seo, Jong-Hwa Won, Min-Kyu Hur
Abstract: Methods are provided for producing a human embryo capable of developing to the blastocyst stage. The method includes transferring a human somatic cell genome into a mature human oocyte by nuclear transfer and activating the oocyte, without removing the oocyte genome. Pluripotent human embryonic stem cells, and methods of obtaining these, are also provided.
Type:
Grant
Filed:
November 22, 2011
Date of Patent:
June 10, 2014
Assignee:
The New York Stem Cell Foundation
Inventors:
Dietrich M. Egli, Scott A. Noggle, Kevin C. Eggan
Abstract: An engineered three-dimensional structure includes living cells cohered with each other. The living cells suitably include Schwann cells and at least one other type of cell. The cells accompanying the Schwann cells can suitably be bone marrow stem cells or another type of cell having one or more anti-inflammatory properties. The structure is suitably a graft that facilitates restorative axon growth when the graft is implanted between the proximal and distal stubs of a severed nerve in a living organism. The graft can optionally include a plurality of acellular conduits extending between opposite axial ends of the graft. Bio-printing techniques can be used to assemble a three-dimensional construct that becomes through maturation an axon-guiding graft, by stacking a plurality of multicellular bodies, each of which includes a plurality of living cells cohered to one another to sufficiently to avoid collapsing when the multicellular bodies are stacked to form the structure.
Type:
Grant
Filed:
February 2, 2011
Date of Patent:
June 10, 2014
Assignee:
The Curators of the University of Missouri
Inventors:
Gabor Forgacs, Stephen H. Colbert, Bradley A. Hubbard, Francoise Marga, Dustin Christiansen
Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.
Type:
Grant
Filed:
August 13, 2007
Date of Patent:
June 10, 2014
Assignee:
Intrexon Corporation
Inventors:
Robert Eugene Hormann, Colin M. Tice, Orestes Chortyk, Howard Smith, Thomas Meteyer
Abstract: Choroid plexus epithelial cells are generated in a culture medium using embryonic stem cells and adding an effective amount of bone morphogenetic protein and/or other members of the transforming growth factor beta (TGF-beta) superfamily. Generation of such choroid plexus epithelial cells are confirmed using a combination of genetic markers, antibodies, histology inspection, functional assays, and integration into the endogenous choroid plexus in mice.
Type:
Grant
Filed:
February 9, 2012
Date of Patent:
June 10, 2014
Assignee:
The Regents of the University of California
Abstract: The present invention relates to a method of treatment of mesenchymal stem cells, preferably from adipose origin, comprising mainly two stages, firstly the collection and isolation of mesenchymal stem cells, and secondly, a period of growth and specific treatment of cells in a conditioning or treatment medium with an oxidizing agent. The invention also comprises the cells obtained directly through the method and its use in treating diseases caused by or associated with oxidative stress.
Type:
Application
Filed:
July 6, 2011
Publication date:
June 5, 2014
Applicant:
HISTOCELL S.L.
Inventors:
Maria Begona Castro, Javier Diez Garcia
Abstract: Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.
Type:
Application
Filed:
November 5, 2013
Publication date:
June 5, 2014
Applicant:
ViaCyte, Inc.
Inventors:
Kevin A. D'Amour, Anne Bang, Emmanuel E. Baetge